Stifel Financial Corp Makes New Investment in Sana Biotechnology, Inc. (NASDAQ:SANA)

Stifel Financial Corp purchased a new stake in Sana Biotechnology, Inc. (NASDAQ:SANA) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 10,265 shares of the company’s stock, valued at approximately $43,000.

Several other large investors have also recently modified their holdings of SANA. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Sana Biotechnology by 20.6% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 29,858 shares of the company’s stock worth $163,000 after buying an additional 5,090 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of Sana Biotechnology by 2.8% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 253,899 shares of the company’s stock worth $1,056,000 after acquiring an additional 6,823 shares during the period. Arizona State Retirement System boosted its holdings in Sana Biotechnology by 36.7% in the second quarter. Arizona State Retirement System now owns 37,028 shares of the company’s stock valued at $202,000 after acquiring an additional 9,940 shares during the last quarter. Blue Trust Inc. boosted its holdings in Sana Biotechnology by 1,246.6% in the third quarter. Blue Trust Inc. now owns 13,129 shares of the company’s stock valued at $55,000 after acquiring an additional 12,154 shares during the last quarter. Finally, Algert Global LLC bought a new position in Sana Biotechnology during the 2nd quarter worth approximately $73,000. Institutional investors own 88.23% of the company’s stock.

Sana Biotechnology Price Performance

NASDAQ:SANA opened at $1.61 on Tuesday. Sana Biotechnology, Inc. has a twelve month low of $1.52 and a twelve month high of $12.00. The company has a fifty day moving average of $2.68 and a 200-day moving average of $4.28. The firm has a market capitalization of $359.46 million, a P/E ratio of -1.15 and a beta of 1.33.

Sana Biotechnology (NASDAQ:SANA) last posted its quarterly earnings results on Friday, November 8th. The company reported ($0.25) EPS for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.01. On average, analysts anticipate that Sana Biotechnology, Inc. will post -1.16 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms have recently commented on SANA. HC Wainwright reaffirmed a “buy” rating and issued a $8.00 price objective on shares of Sana Biotechnology in a research note on Wednesday, November 27th. JMP Securities cut shares of Sana Biotechnology from an “outperform” rating to a “market perform” rating in a research report on Tuesday, November 5th.

Sana Biotechnology Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.